Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05741112 · ClinicalTrials.gov registry record · NA

The Long COVID-19 Wearable Device Study

A NA study of Long COVID and Chronic Fatigue Syndrome, sponsored by Scripps Translational Science Institute.

Recruiting
Registry status
NA
Development phase
100,500
Enrollment target
1
Study location

NCT05741112 is a NA study of Long COVID and Chronic Fatigue Syndrome that is actively recruiting participants, run by Scripps Translational Science Institute. The registered enrollment target is 100,500 participants, above the 178-participant average among 50 other Long COVID trials with a reported enrollment target (56361% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05741112, a NA study of Long COVID and Chronic Fatigue Syndrome, is actively recruiting participants, sponsored by Scripps Translational Science Institute.

RECRUITING
Registry status
NA
Development phase
100,500 participants
Enrollment target
1
Study location

Study Summary

To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.

Interventions

  • DEVICE Wearable device

Study Locations (1)

California

  • Scripps Research - La Jolla

Trial Details

FieldValue
Enrollment Target 100,500 participants
Start Date 2023-11-16
Est. Completion 2025-12-01
Phase NA

What the Registry Record Tells You About NCT05741112

The ClinicalTrials.gov registry entry for NCT05741112 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 178-participant average among 50 other Long COVID trials with a reported enrollment target (56361% higher). The listed sponsor is Scripps Translational Science Institute, which has 41 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Long COVID appearing as the primary indexed condition, and to 1 intervention - of which Wearable device is the first listed.

NCT05741112 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05741112 about?

NCT05741112 is a clinical study titled "The Long COVID-19 Wearable Device Study". To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.

What is the current status of trial NCT05741112?

This trial is currently recruiting. It is a NA study. The enrollment target is 100,500 participants. The study started on 2023-11-16. Estimated completion is 2025-12-01.

What conditions does trial NCT05741112 study?

This clinical trial studies the following conditions: Long COVID, Chronic Fatigue Syndrome, Postural Orthostatic Tachycardia Syndrome, Dysautonomia, Myalgic Encephalomyelitis.

What interventions are being tested in trial NCT05741112?

The interventions under investigation include: Wearable device (DEVICE).

Who is sponsoring clinical trial NCT05741112?

This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05741112 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Long COVID

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.